

MEDICAL ASSISTANCE BULLETIN

ISSUE DATE

March 12, 2021

EFFECTIVE DATE

February 27, 2021

NUMBER

01-21-01, 08-21-02, 09-21-01, 24-21-01, 31-21-01, 33-21-01

SUBJECT

Administration of SARS-CoV-2 Vaccine Manufactured by Janssen Biotech, Inc.

BY

Sally A. Kozak, Deputy Secretary

Office of Medical Assistance Programs

Sally a. Kozal

IMPORTANT REMINDER: All providers must revalidate the Medical Assistance (MA) enrollment of each service location every 5 years. Providers should log into PROMISe to check the revalidation dates of each service location and submit revalidation applications at least 60 days prior to the revalidation dates. Enrollment (revalidation) applications may be found at: https://www.dhs.pa.gov/providers/Providers/Pages/PROMISe-Enrollment.aspx.

PURPOSE:

The purpose of this bulletin is to inform Medical Assistance (MA) providers that the Department of Human Services (Department) added Current Procedural Terminology (CPT) code 0031A to the MA Program Fee Schedule for the administration of the novel coronavirus (SARS-CoV-2) vaccine manufactured by Janssen Biotech, Inc. in response to the coronavirus disease 2019 (COVID-19) pandemic.

SCOPE:

This bulletin applies to all physicians, certified registered nurse practitioners, certified nurse midwives, outpatient hospital clinics, independent medical surgical clinics, and licensed pharmacies enrolled in the MA Program who administer immunizations to MA beneficiaries in the Fee-for-Service (FFS) delivery system or through the MA managed care organizations (MCOs) in Physical Health HealthChoices and Community HealthChoices. Providers rendering services to MA beneficiaries in the managed care delivery system should contact the appropriate MCO with any billing questions.

BACKGROUND/DISCUSSION:

On January 20, 2021, the American Medical Association (AMA), in collaboration with the Centers for Medicare & Medicaid Services (CMS), established a new CPT code for the administration of the SARS-CoV-2 vaccine manufactured by Janssen Biotech, Inc. The code

COMMENTS AND QUESTIONS REGARDING THIS BULLETIN SHOULD BE DIRECTED TO:

The appropriate toll-free number for your provider type.

Visit the Office of Medical Assistance Programs website at:

https://www.dhs.pa.gov/providers/Providers/Pages/Health%20Care%20for%20Providers/Contact-Information-for-Providers.aspx. is distinct to the SARS-CoV-2 vaccine below. This level of specificity offers the ability to track each vaccine, even when the vaccine product is not reported, such as when the vaccine is available at no cost.

In response, the Department added CPT code 0031A to the MA Program Fee Schedule, effective February 26, 2021, which may be used for dates of service on and after February 27, 2021, the date that the SARS-CoV-2 vaccine manufactured by Janssen Biotech, Inc. received Emergency Use Authorization by the United States Food and Drug Administration. This code is to be used by providers in both the FFS and managed care delivery systems to enable the Department to identify the specific SARS-CoV-2 vaccines that have been administered.

PROCEDURE:

MA providers in both the FFS and managed care delivery systems are to bill for the administration of the SARS-CoV-2 vaccine manufactured by Janssen Biotech, Inc. to MA beneficiaries using the CPT code below.

Vaccine Manufacturer	Code	Code Description				
Janssen Biotech, Inc.	0031A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, single dose				

Attached is the "Addition to the Medical Assistance Program Fee Schedule: Procedure Code for the Administration of SARS-CoV-2 Vaccine Manufactured by Janssen Biotech, Inc.". The attachment identifies the procedure code, national code description, provider type, provider specialty, place of service, pricing and/or informational modifiers if applicable, and MA fee for the procedure code for providers submitting MA FFS claims.

Providers may access the online version of the MA Program Fee Schedule on the Department's website at:

 $\frac{https://www.dhs.pa.gov/providers/Providers/Pages/Health\%20Care\%20for\%20Providers/MA-Fee-Schedule.aspx.}{$

MA providers may also bill the MA Program for the vaccine for MA eligible beneficiaries by indicating, on the claim submission, the appropriate National Drug Code and the units dispensed for the vaccine. Providers may access the online version of the MA Drug Fee Schedule on the Department's website at: https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/default.aspx.

Providers may not bill the MA Program for a vaccine they receive at no cost, including SARS-CoV-2 vaccines purchased by the federal government.

For information on how licensed pharmacies enrolled in the MA Program who provide services to MA beneficiaries should bill for the administration of SARS-CoV-2 vaccines by a pharmacist, please refer to MA Bulletin 01-20-60, "SARS-CoV-2 Vaccine Administration by

Pharmacists", issued December 30, 2020, at the link below: https://www.dhs.pa.gov/docs/Publications/Documents/FORMS%20AND%20PUBS%20OMAP/MAB2020123001.pdf.

Additional information and guidance pertaining to the SARS-CoV-2 vaccines can be found at the following links:

- American Medical Association <u>https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-coding-and-guidance</u>.
- Centers for Disease Control and Prevention https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html.
- Centers for Medicare & Medicaid Services
 https://www.medicaid.gov/resources-for-states/disaster-response-toolkit/coronavirus-disease-2019-covid-19/index.html.
- PA Department of Health
 1-877-PA HEALTH (1-877-724-3258)
 https://www.health.pa.gov/Pages/default.aspx.

ATTACHMENT:

Addition to the Medical Assistance Program Fee Schedule: Procedure Code for the Administration of SARS-CoV-2 Vaccine Manufactured by Janssen Biotech, Inc.

Addition to the Medical Assistance Program Fee Schedule: Procedure Codes for the Administration of SARS-CoV-2 Vaccine Manufactured by Janssen Biotech, Inc.

Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
	Immunization administration by								
	intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-								
	CoV-2) (coronavirus disease [COVID-19])								
	vaccine, DNA, spike protein, adenovirus								
	type 26 (Ad26) vector, preservative free,								
	5x1010 viral particles/0.5mL dosage, single								
0031A	dose	01	183	22			\$28.39	No	once per da
	Immunization administration by								
	intramuscular injection of severe acute								
	respiratory syndrome coronavirus 2 (SARS-								
	CoV-2) (coronavirus disease [COVID-19])								
	vaccine, DNA, spike protein, adenovirus								
	type 26 (Ad26) vector, preservative free,								
	5x1010 viral particles/0.5mL dosage, single								
0031A	dose	08	082	49			\$28.39	No	once per day
	Immunization administration by								
	intramuscular injection of severe acute								
	respiratory syndrome coronavirus 2 (SARS-								
	CoV-2) (coronavirus disease [COVID-19])								
	vaccine, DNA, spike protein, adenovirus								
	type 26 (Ad26) vector, preservative free,								
	5x1010 viral particles/0.5mL dosage, single								
0031A	dose	09	All	11, 12, 31, 32			\$28.39	No	once per day
	Immunization administration by								
	intramuscular injection of severe acute								
	respiratory syndrome coronavirus 2 (SARS-								
	CoV-2) (coronavirus disease [COVID-19])								
	vaccine, DNA, spike protein, adenovirus								
	type 26 (Ad26) vector, preservative free,								
00214	5x1010 viral particles/0.5mL dosage, single	24	240 247	11 21 22 00			\$28.39	No	once per da
0031A	dose	24	240, 247	11, 31, 32, 99			\$28.39	No	Touce bei ga

	0031A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, single dose	31	All	11, 12, 31, 32		\$28.39	No	once per day
	00214	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, single		235	11 12		\$20.20	Mo	ance per day
(0031A	dose	33	335	11, 12		\$28.39	No	once per